Reuters logo
1 个月内
BRIEF-Mabvax Therapeutics commences patient dosing in MVT-1075 radioimmunotherapy TRIAL
2017年6月27日 / 下午12点34分 / 1 个月内

BRIEF-Mabvax Therapeutics commences patient dosing in MVT-1075 radioimmunotherapy TRIAL

1 分钟阅读

June 27 (Reuters) - Mabvax Therapeutics Holdings Inc

* Mabvax Therapeutics commences patient dosing in MVT-1075 radioimmunotherapy phase 1 clinical trial for the treatment of pancreatic, colon and lung cancers

* Company expects to report interim results by end of 2017 for MVT-1075 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below